63 related articles for article (PubMed ID: 9422791)
1. Baculovirus-mediated expression of truncated modular fragments from the catalytic region of human complement serine protease C1s. Evidence for the involvement of both complement control protein modules in the recognition of the C4 protein substrate.
Rossi V; Bally I; Thielens NM; Esser AF; Arlaud GJ
J Biol Chem; 1998 Jan; 273(2):1232-9. PubMed ID: 9422791
[TBL] [Abstract][Full Text] [Related]
2. Molecular Interactions Required for Activation of Complement Component C2 Include Exosites Located on the Serine Protease Domain of C1s and Mannose-Binding Lectin Associated Protease-2.
Hor L; Pan J; Pike RN; Wijeyewickrema LC
J Immunol; 2024 Apr; 212(7):1172-1177. PubMed ID: 38372634
[TBL] [Abstract][Full Text] [Related]
3. HMGB1 cleavage by complement C1s and its potent anti-inflammatory product.
Lorvellec M; Chouquet A; Koch J; Bally I; Signor L; Vigne J; Dalonneau F; Thielens NM; Rabilloud T; Dalzon B; Rossi V; Gaboriaud C
Front Immunol; 2023; 14():1151731. PubMed ID: 37180096
[TBL] [Abstract][Full Text] [Related]
4. Outer surface lipoproteins from the Lyme disease spirochete exploit the molecular switch mechanism of the complement protease C1s.
Garrigues RJ; Thomas S; Leong JM; Garcia BL
J Biol Chem; 2022 Nov; 298(11):102557. PubMed ID: 36183830
[TBL] [Abstract][Full Text] [Related]
5. The molecular determinants of classical pathway complement inhibition by OspEF-related proteins of Borrelia burgdorferi.
Thomas S; Schulz AM; Leong JM; Zeczycki TN; Garcia BL
J Biol Chem; 2024 May; 300(5):107236. PubMed ID: 38552741
[TBL] [Abstract][Full Text] [Related]
6. Molecular determinants of the substrate specificity of the complement-initiating protease, C1r.
Wijeyewickrema LC; Yongqing T; Tran TP; Thompson PE; Viljoen JE; Coetzer TH; Duncan RC; Kass I; Buckle AM; Pike RN
J Biol Chem; 2013 May; 288(22):15571-80. PubMed ID: 23589288
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the C1s Protease and the Classical Complement Pathway by 6-(4-Phenylpiperazin-1-yl)Pyridine-3-Carboximidamide and Chemical Analogs.
Xu X; Herdendorf TJ; Duan H; Rohlik DL; Roy S; Zhou H; Alkhateeb H; Khandelwal S; Zhou Q; Li P; Arepally GM; Walker JK; Garcia BL; Geisbrecht BV
J Immunol; 2024 Feb; 212(4):689-701. PubMed ID: 38149922
[TBL] [Abstract][Full Text] [Related]
8. Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s.
Daugan MV; Revel M; Russick J; Dragon-Durey MA; Gaboriaud C; Robe-Rybkine T; Poillerat V; Grunenwald A; Lacroix G; Bougouin A; Meylan M; Verkarre V; Oudard SM; Mejean A; Vano YA; Perkins G; Validire P; Cathelineau X; Sanchez-Salas R; Damotte D; Fremeaux-Bacchi V; Cremer I; Sautès-Fridman C; Fridman WH; Roumenina LT
Cancer Immunol Res; 2021 Aug; 9(8):891-908. PubMed ID: 34039653
[TBL] [Abstract][Full Text] [Related]
9. Quantitative fluorescence resonance energy transfer-based immunoassay for activated complement C1s.
Ye J; Xu J; Zhang C; Zhu L; Xia S
Front Immunol; 2023; 14():1081793. PubMed ID: 36761732
[TBL] [Abstract][Full Text] [Related]
10. Sutimlimab: First Approval.
Dhillon S
Drugs; 2022 May; 82(7):817-823. PubMed ID: 35412113
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a Novel Series of Potent, Selective, Orally Available, and Brain-Penetrable C1s Inhibitors for Modulation of the Complement Pathway.
Ikeda Z; Kamei T; Sasaki Y; Reynolds M; Sakai N; Yoshikawa M; Tawada M; Morishita N; Dougan DR; Chen CH; Levin I; Zou H; Kuno M; Arimura N; Kikukawa Y; Kondo M; Tohyama K; Sato K
J Med Chem; 2023 May; 66(9):6354-6371. PubMed ID: 37120845
[TBL] [Abstract][Full Text] [Related]
12. Noncanonical Functions of C1s Complement Its Canonical Functions in Renal Cancer.
Magrini E; Garlanda C
Cancer Immunol Res; 2021 Aug; 9(8):855. PubMed ID: 34158282
[TBL] [Abstract][Full Text] [Related]
13. Catalytic, selective, and stereocontrolled construction of C4 quaternary and homobenzylic dihydroisoquinolones by sp
Beng TK; Moreno A
RSC Adv; 2020 Feb; 10(15):8805-8809. PubMed ID: 35496534
[TBL] [Abstract][Full Text] [Related]
14. Integrated pan-cancer analysis of CSMD2 as a potential prognostic, diagnostic, and immune biomarker.
Zhang H; Huang T; Ren X; Fang X; Chen X; Wei H; Sun W; Wang Y
Front Genet; 2022; 13():918486. PubMed ID: 36061177
[TBL] [Abstract][Full Text] [Related]
15. Two Different Missense
Bally I; Dalonneau F; Chouquet A; Gröbner R; Amberger A; Kapferer-Seebacher I; Stoiber H; Zschocke J; Thielens NM; Rossi V; Gaboriaud C
Front Immunol; 2019; 10():2962. PubMed ID: 31921203
[TBL] [Abstract][Full Text] [Related]
16. FIBCD1 overexpression predicts poor prognosis in patients with hepatocellular carcinoma.
Wang Y; Sun M; Liu J; Liu Y; Jiang C; Zhu H; Wang W; Wang Y
Oncol Lett; 2020 Jan; 19(1):795-804. PubMed ID: 31897196
[TBL] [Abstract][Full Text] [Related]
17. Insights into IgM-mediated complement activation based on in situ structures of IgM-C1-C4b.
Sharp TH; Boyle AL; Diebolder CA; Kros A; Koster AJ; Gros P
Proc Natl Acad Sci U S A; 2019 Jun; 116(24):11900-11905. PubMed ID: 31147461
[TBL] [Abstract][Full Text] [Related]
18. Structural and Functional Characterization of a Single-Chain Form of the Recognition Domain of Complement Protein C1q.
Moreau C; Bally I; Chouquet A; Bottazzi B; Ghebrehiwet B; Gaboriaud C; Thielens N
Front Immunol; 2016; 7():79. PubMed ID: 26973654
[TBL] [Abstract][Full Text] [Related]
19. Deciphering the fine details of c1 assembly and activation mechanisms: "mission impossible"?
Gaboriaud C; Ling WL; Thielens NM; Bally I; Rossi V
Front Immunol; 2014; 5():565. PubMed ID: 25414705
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
